Biosimilars and Biobetters September 24, 2012

We invite you to attend our third annual Biosimilars and Biobetters conference that promises to present attendees with the perfect forum to discuss the rising development cost of biosimilars and successful marketing and pricing strategies, with a focus on case studies from those who are both developing and distributing follow on biologics. With more in depth guidelines being issued by regulatory bodies on the development of biosimilars, this event is not to be missed!

10 reasons to attend include:

• Gain the insight you require to implement comparative clinical trials of the latest developments in the biosimilar pipelines.
• Evaluate current and future developments in intellectual property and patent protection
• Hear from industry and academia on the development process from a pre-clinical perspective
• Discover the impact of recent guidelines issued by regulatory bodies such as the FDA and EMEA
• Discuss biosimilars vs. biobetters, which one is the better strategy
• Learn from top pharma companies, including Teva and Sanofi, new variations in global regulatory strategies for biosimilar development
• Assess market access pathways and learn from past success stories
• Develop plans and methods for biosimilar and biobetter drug design and clinical testing
• Examine the opportunities for long term growth in follow on biologics
• Network with fellow pharma professionals from the UK’s top companies

Official Website: http://www.smi-online.co.uk/goto/biosimilars-biobetters52.asp